Skip to content
value.today

Nora Therapeutics, Inc.

🇺🇸 Owings Mills, Maryland, USABiotechnologyFounded 2007

Formerly Nora, LLC

Total raised
$37 M
4 rounds on record
Latest round
$1 M
Sep 2015
First round on record
Mar 2009
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Nora Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2015$1 MNo. 4Under $2 million

Nora Therapeutics, Inc.: Raise no. 4, Sep 2015

Investors in this round

6 investors had bought by the notice of Oct 13, 2015: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $3 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey K. Tong · Executive Officer, Director
  • Anupam K. Dalal · Director
  • Chen K. Yu · Director
  • David K. Schnell · Director
  • Dennis K. Fenton · Director
  • Donald K. Hayden, Jr. · Director
  • Joseph L. Turner, Jr. · Director
  • Martin K. Vogelbaum · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jeffrey K. Tong, President & CEO. Source: SEC Form D, newest notice filed Oct 13, 2015. Read the notice at the SEC.

debt, optionsSEC
Apr 2014$18 MNo. 3$10 to $50 million

Nora Therapeutics, Inc.: Raise no. 3, Apr 2014

Investors in this round

6 investors had bought by the notice of Apr 23, 2014: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$18 M of $18 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey K. Tong · Executive Officer, Director
  • Bryant E. Fong · Director
  • Chen E. Yu · Director
  • David E. Schnell · Director
  • Dennis J. Fenton · Director
  • Donald J. Hayden, Jr. · Director
  • Martin J. Vogelbaum · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jeffrey K. Tong, President and CEO. Source: SEC Form D, newest notice filed Apr 23, 2014. Read the notice at the SEC.

equitySEC
Sep 2010$15 MNo. 2$10 to $50 million

Nora Therapeutics, Inc.: Raise no. 2, Sep 2010

Investors in this round

5 investors had bought by the notice of Sep 23, 2010: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $33 M offered; $18 M still to sell
Smallest investment taken
$12,950
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alan K Colowick · Executive Officer, Director
  • Christopher B. McClain · Executive Officer
  • Darryl L. Carter · Executive Officer
  • Jeffrey K Tong · Executive Officer, Director
  • Bryant E. Fong · Director
  • Chen E. Yu · Director
  • David E. Schnell · Director
  • Donald J. Hayden, Jr. · Director
  • Martin K Vogelbaum · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jeffrey K. Tong, PhD, President and CEO. Source: SEC Form D, newest notice filed Sep 23, 2010. Read the notice at the SEC.

equitySEC
Mar 2009$3 MNo. 1$2 to $10 million

Nora Therapeutics, Inc.: Raise no. 1, Mar 2009

Investors in this round

4 investors had bought by the notice of Jun 2, 2010: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $25 M offered; $22 M still to sell
Smallest investment taken
$919
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher B. McClain · Executive Officer
  • Darryl L. Carter · Executive Officer
  • Bryant E. Fong · Director
  • Chen E. Yu · Director
  • David E. Schnell · Director
  • Donald J. Hayden, Jr. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Christopher B. McClain, Treasurer. Source: SEC Form D and 1 amendment, newest notice filed Jun 2, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Nora Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2015).

    SEC Form D · Oct 2015

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2015

That is all the official record says: Nora Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Nora Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 6 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Nora Therapeutics, Inc.
NameRoleNamed in
Jeffrey K. TongExecutive officerOct 2015
Alan K ColowickExecutive officerSep 2010
Christopher B. McClainExecutive officerSep 2010
Darryl L. CarterExecutive officerSep 2010
Jeffrey K TongExecutive officerSep 2010
Julie McHughExecutive officerApr 2009
Anupam K. DalalDirectorOct 2015
Chen K. YuDirectorOct 2015
David K. SchnellDirectorOct 2015
Dennis K. FentonDirectorOct 2015
Donald K. Hayden, Jr.DirectorOct 2015
Jeffrey K. TongDirectorOct 2015
Joseph L. Turner, Jr.DirectorOct 2015
Martin K. VogelbaumDirectorOct 2015
Bryant E. FongDirectorApr 2014
Chen E. YuDirectorApr 2014
David E. SchnellDirectorApr 2014
Dennis J. FentonDirectorApr 2014
Donald J. Hayden, Jr.DirectorApr 2014
Martin J. VogelbaumDirectorApr 2014
Alan K ColowickDirectorSep 2010
Jeffrey K TongDirectorSep 2010
Martin K VogelbaumDirectorSep 2010
Chen YuDirectorApr 2009
David SchnellDirectorApr 2009
Julie McHughDirectorApr 2009